Holen Sie sich die Stockscreener-App
63.04
1.08%
-0.69
Handel nachbörslich:
62.00
-1.04
-1.65%
Schlusskurs vom Vortag:
$63.73
Offen:
$64
24-Stunden-Volumen:
6.01M
Relative Volume:
2.75
Marktkapitalisierung:
$6.62B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+20.05%
1M Leistung:
+20.47%
6M Leistung:
+161.47%
1J Leistung:
+0.00%
1-Tages-Spanne:
$62.48
$64.33
1-Wochen-Bereich:
$51.84
$66.10
52-Wochen-Spanne:
$12.30
$66.10
Metsera Inc Stock (MTSR) Company Profile
Firmenname
Metsera Inc
Sektor
Branche
Telefon
(212) 784-6595
Adresse
3 WORLD TRADE CENTER, NEW YORK
Vergleichen Sie MTSR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
63.04 | 6.71B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-09-09 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-02-25 | Eingeleitet | BofA Securities | Buy |
| 2025-02-25 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Metsera Inc Aktie (MTSR) Neueste Nachrichten
Pfizer Sues Novo Nordisk, Metsera in Acquisition Battle - 조선일보
Metsera (MTSR) Jumps 20% as Big Pharma Battle Heats Up Over Takeover - MSN
Pfizer sues Novo Nordisk and Metsera - MarketScreener
Pfizer (PFE) Sues Over Metsera Acquisition Bid - GuruFocus
Pfizer sues Metsera, Novo Nordisk to block rival bid - Seeking Alpha
Key facts: Pfizer to report Q3 earnings on Nov 4; faces legal battle over Metsera - TradingView
Metsera Inc. stock chart pattern explainedJuly 2025 Opening Moves & Free Weekly Watchlist of Top Performers - newser.com
Why Metsera Inc. stock attracts global investorsWall Street Watch & Low Risk High Reward Ideas - newser.com
Pfizer sues to block Novo Nordisk's Metsera takeover bid - pharmaphorum
Real Madrid to Seek Damages After Antitrust Ruling Against UEFA - PYMNTS.com
Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk - MSN
Novo Nordisk submits proposal to acquire Metsera - Medical Dialogues
The week in pharma: action, reaction and insight – week to October 31 - The Pharma Letter
Why Pfizer Can Still Prevail in the Obesity Fight With Novo NordiskWSJ - The Wall Street Journal
What Fibonacci levels say about Metsera Inc. reboundAnalyst Downgrade & Entry and Exit Point Strategies - newser.com
Metsera Inc. $MTSR Shares Sold by Jennison Associates LLC - MarketBeat
Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera - MSN
10 Stocks With Easy 20-40% Gains - Insider Monkey
Is Metsera Inc. forming a bottoming baseStop Loss & Technical Pattern Based Signals - newser.com
Key facts: Pfizer gains antitrust approval for Metsera; faces lawsuits - TradingView
Pfizer sues Metsera, Novo in effort to enforce buyout deal - BioPharma Dive
Pfizer Sues Metsera to Block Novo Nordisk’s $9B “Bribe” Deal - USA Herald
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid - RNZ
Pfizer goes to court to stop Novo Nordisk bid for Metsera - The Pharma Letter
Is Metsera Inc. building a consolidation base2025 Analyst Calls & Fast Entry High Yield Stock Tips - newser.com
Novo makes a play for Metsera; This week’s other big deal; Earnings in full swing; and more - Endpoints News
Pfizer sues to block Novo Nordisk’s bid for Metsera in high-stakes pharma clash - TradingView
Pfizer Sues to Block Novo Bid for Obesity Drugmaker Metsera - MSN
Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer - MSN
Pfizer Sues Metsera, Novo Nordisk Over $9B Buyout 'Bribe' - Law360
Key facts: Novo Nordisk bids $9B for Metsera; job cuts near completion - TradingView
Pfizer secures early termination, launches lawsuit over Metsera deal - Global Competition Review
Pfizer sues to stop rival bid for drugmaker Metsera by Denmark’s Novo Nordisk - CBS 42
Pfizer files lawsuit to block Novo Nordisk's bid for Metsera - Axios
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid By Reuters - Investing.com
Metsera (MTSR) Responds to Pfizer's Legal Action - GuruFocus
Pfizer Sues Seeking to Block Novo Nordisk’s Effort to Undo Weight-Loss Drug DealWSJ - The Wall Street Journal
Pfizer Gets Nod to Proceed With Metsera Deal From US Regulators - Bloomberg.com
Pfizer Sues Novo, Metsera Over $6.5 Billion Bid - Investor's Business Daily
Metsera Issues Statement in Response to Litigation - Yahoo Finance
Pfizer (PFE) Sues Metsera and Novo Nordisk Over Disputed Obesity Drug Merger - TipRanks
Pfizer sues Novo Nordisk, Metsera for breach of merger agreement - statnews.com
Pfizer sues Metsera and Novo Nordisk over merger agreement breach - Investing.com
Pfizer Files Lawsuit Against Metsera And Its Directors And Novo Nordisk For Breach Of Merger Agreement - TradingView
Pfizer sues Metsera, Novo Nordisk for merger deal breach - breakingthenews.net
Pfizer (PFE) Granted Early Termination for Metsera Acquisition - GuruFocus
Pfizer sues Metsera and Novo Nordisk over merger agreement breach By Investing.com - Investing.com Nigeria
Pfizer sues Metsera, Novo Nordisk over breach of merger deal By Reuters - Investing.com
Pfizer sues Metsera, Novo Nordisk over breach of merger deal - Reuters
Novo Nordisk (NVO) in Pursuit of Metsera Amid Pfizer's Regulator - GuruFocus
Pfizer wins early US antitrust nod for Metsera deal - Yahoo Finance
Finanzdaten der Metsera Inc-Aktie (MTSR)
Es liegen keine Finanzdaten für Metsera Inc (MTSR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):